KAPIL COTEX LTD.

Skybiotech Healthcare Ltd announced that its Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The results, prepared in accordance with Indian Accounting Standard 34, were reviewed by SPD & Associates, Chartered Accountants. The company has submitted these results along with the Limited Review Report as per SEBI (LODR) Regulations, 2015.

Skybiotech Healthcare Ltd (formerly Kapil Cotex Limited) has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The results were approved by the Board of Directors on November 10, 2026. A limited review report from SPD & Associates, Chartered Accountants, has also been submitted. The filing includes standalone financial results prepared in accordance with Indian Accounting Standard 34.

Skybiotech Healthcare Ltd has announced that its Board of Directors will convene on November 10, 2026. The primary agenda item for this meeting is the consideration and approval of the company's un-audited financial results for the quarter and half-year ended September 30, 2026. A limited review report will also be presented. The meeting will adhere to SEBI (LODR) Regulations, 2015, specifically Regulation 29(1)(a) concerning board meeting disclosures.

Skybiotech Healthcare Ltd has announced the closure of its trading window from October 1st, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended September 30th, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The company will also inform the stock exchanges in due course about the board meeting date to consider and approve these financial results.

Skybiotech Healthcare Ltd has announced its 43rd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 AM at its registered office in Chh. Sambhaji Nagar (Aurangabad). The meeting will cover ordinary business, including the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Key agenda items also include the re-appointment of Mr. Prakashchandra Rathi as a director and the appointment of M/s. SPD & Associates as statutory auditors for a term of five years. The company has commenced dispatch of the AGM notice and Annual Report for FY2025-26 to its members.

Skybiotech Healthcare Ltd (formerly Kapil Cotex Limited) has submitted its Annual Report for the Financial Year 2025-2026, as per SEBI regulations. The report is available on the company's website. It details corporate information including the Board of Directors, Compliance Officer, CFO, Statutory Auditors, and Secretarial Auditor. The report also outlines the structure of the Annual Report, including the Board Report, Management Discussion and Analysis, Independent Auditor's Report, Financial Statements (Standalone and Consolidated), and Notes to Accounts. The filing also lists members of the Audit Committee, Stakeholder Relationship Committee, and Nomination and Remuneration Committee.

Skybiotech Healthcare Ltd announced its Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Board of Directors approved these results and took on record the Limited Review Report from the Statutory Auditors, SPD & Associates. The board meeting was held on August 14, 2026, commencing at 5:00 PM and concluding at 8:45 PM.

Skybiotech Healthcare Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Board also took on record the Limited Review Report issued by the Statutory Auditors. The meeting commenced at 5:00 PM and concluded at 8:45 PM on the same day.

Skybiotech Healthcare Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item for this meeting is to consider and approve the company's un-audited financial results for the quarter ending June 30, 2026. A limited review report for these results will also be presented. The meeting will follow SEBI (LODR) Regulations, 2015, and may address other business matters with the chair's permission.

Skybiotech Healthcare Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ended June 30, 2026. This measure aligns with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.